Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives (original) (raw)
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
- J Tack1,
- M van Outryve2,
- G Beyens3,
- R Kerstens3,
- L Vandeplassche3
- 1
Division of Gastroenterology, University Hospital, Leuven, Belgium - 2
Division of Gastroenterology, University Hospital, Edegem, Belgium - 3
Movetis NV, Turnhout, Belgium - Dr J Tack, Division of Gastroenterology, Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Jan.Tack{at}med.kuleuven.be
Abstract
Objective: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT4 receptor agonist, in patients with chronic constipation.
Methods: In this multicentre, randomised, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/week) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 weeks. The primary efficacy endpoint was the proportion of patients reaching three or more SCBM/week. The key secondary efficacy endpoint was the proportion of patients having an increase of one or more SCBM/week. The primary QOL endpoint was the patient assessment of constipation QOL satisfaction subscale score. Safety parameters included adverse events, laboratory values and cardiovascular events.
Results: Efficacy was evaluated over 713 patients. Averaged over 12 weeks, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had three or more SCBM/week (or normalisation of bowel function) compared with placebo (9.6%). Similar results were seen in the subgroup (83%) of patients dissatisfied with previous laxative treatment. Both doses of prucalopride also significantly improved secondary efficacy and QOL endpoints, including the proportion of patients with an increase of one or more SCBM/week, evacuation completeness, perceived disease severity and treatment effectiveness and QOL. Prucalopride 4 mg significantly reduced the need for straining versus placebo (p<0.05). The most frequent treatment-related adverse events were headache and diarrhoea. Both doses of prucalopride were safe and well tolerated.
Conclusion: Prucalopride significantly and consistently improved bowel function, associated symptoms and satisfaction in chronically constipated patients.
Trial registration number: NCT00488137.
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Linked Articles
- Digest
Gut 2009; 58 i-ii Published Online First: 11 Feb 2009. - Miscellanea
BMJ Publishing Group Ltd and British Society of Gastroenterology
Gut 2012; 61 1298-1298 Published Online First: 13 Aug 2012. doi: 10.1136/gut.2008.162404corr1